Sanjivani Paranteral manufactures and exports life-saving sterile injectables, intravenous fluids, and oral solid medicines to over 25 emerging markets. The company operates production facilities in India and has a nutraceutical joint venture in Europe.
The company operates in a highly commoditized generic pharmaceutical space where pricing pressure is intense, evidenced by historically negative net margins and poor ROE. While regulatory approvals and long-standing customer relationships provide a baseline for operations, the lack of durable pricing power or unique intellectual property prevents the formation of a meaningful moat.
Management has recently pivoted toward heavy reinvestment in a new large-volume parenteral facility in Pune and a European nutraceutical venture. While these diversify the business, the historical track record shows capital has often been deployed into low-return or loss-making activities, resulting in an average ROE of -6.7%.
The company's aggressive expansion into a new Pune facility and European nutraceuticals proved to be a classic case of 'diworsification,' where capital was incinerated in low-return ventures. Historical patterns of negative net margins and poor ROE persisted as the company failed to gain pricing power in commoditized markets. The heavy reliance on volatile Middle Eastern and African regions eventually led to a liquidity crunch when geopolitical instability and regulatory bottlenecks in Latin America halted shipments, leaving the company with mountains of unsellable inventory and no cash flow to service its ambitions.
RichFakir rates Sanjivani Paranteral Ltd's business quality as poor — 34/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sanjivani Paranteral Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sanjivani Paranteral Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sanjivani Paranteral Ltd's fair value is about ₹70 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →